Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand.
<h4>Background</h4>Viral load (VL) is recommended for monitoring the response to highly active antiretroviral therapy (HAART) but is not routinely available in most low- and middle-income countries. The purpose of the study was to determine whether a CD4-based monitoring and switching st...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/34088c5dc0be4ad7831a7675568d645b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:34088c5dc0be4ad7831a7675568d645b |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R |
| spellingShingle |
Medicine R Gonzague Jourdain Sophie Le Cœur Nicole Ngo-Giang-Huong Patrinee Traisathit Tim R Cressey Federica Fregonese Baptiste Leurent Intira J Collins Intira J Collins Malee Techapornroong Sukit Banchongkit Sudanee Buranabanjasatean Guttiga Halue Ampaipith Nilmanat Nuananong Luekamlung Virat Klinbuayaem Apichat Chutanunta Pacharee Kantipong Chureeratana Bowonwatanuwong Rittha Lertkoonalak Prattana Leenasirimakul Somboon Tansuphasawasdikul Pensiriwan Sang-A-Gad Panita Pathipvanich Srisuda Thongbuaban Pakorn Wittayapraparat Naree Eiamsirikit Yuwadee Buranawanitchakorn Naruepon Yutthakasemsunt Narong Winiyakul Luc Decker Sylvaine Barbier Suporn Koetsawang Wasna Sirirungsi Kenneth McIntosh Sombat Thanprasertsuk Marc Lallemant PHPT-3 study team Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. |
| description |
<h4>Background</h4>Viral load (VL) is recommended for monitoring the response to highly active antiretroviral therapy (HAART) but is not routinely available in most low- and middle-income countries. The purpose of the study was to determine whether a CD4-based monitoring and switching strategy would provide a similar clinical outcome compared to the standard VL-based strategy in Thailand.<h4>Methods and findings</h4>The Programs for HIV Prevention and Treatment (PHPT-3) non-inferiority randomized clinical trial compared a treatment switching strategy based on CD4-only (CD4) monitoring versus viral-load (VL). Consenting participants were antiretroviral-naïve HIV-infected adults (CD4 count 50-250/mm(3)) initiating non-nucleotide reverse transcriptase inhibitor (NNRTI)-based therapy. Randomization, stratified by site (21 public hospitals), was performed centrally after enrollment. Clinicians were unaware of the VL values of patients randomized to the CD4 arm. Participants switched to second-line combination with confirmed CD4 decline >30% from peak (within 200 cells from baseline) in the CD4 arm, or confirmed VL >400 copies/ml in the VL arm. Primary endpoint was clinical failure at 3 years, defined as death, new AIDS-defining event, or CD4 <50 cells/mm(3). The 3-year Kaplan-Meier cumulative risks of clinical failure were compared for non-inferiority with a margin of 7.4%. In the intent to treat analysis, data were censored at the date of death or at last visit. The secondary endpoints were difference in future-drug-option (FDO) score, a measure of resistance profiles, virologic and immunologic responses, and the safety and tolerance of HAART. 716 participants were randomized, 356 to VL monitoring and 360 to CD4 monitoring. At 3 years, 319 participants (90%) in VL and 326 (91%) in CD4 were alive and on follow-up. The cumulative risk of clinical failure was 8.0% (95% CI 5.6-11.4) in VL versus 7.4% (5.1-10.7) in CD4, and the upper-limit of the one-sided 95% CI of the difference was 3.4%, meeting the pre-determined non-inferiority criterion. Probability of switch for study criteria was 5.2% (3.2-8.4) in VL versus 7.5% (5.0-11.1) in CD4 (p=0.097). Median time from treatment initiation to switch was 11.7 months (7.7-19.4) in VL and 24.7 months (15.9-35.0) in CD4 (p=0.001). The median duration of viremia >400 copies/ml at switch was 7.2 months (5.8-8.0) in VL versus 15.8 months (8.5-20.4) in CD4 (p=0.002). FDO scores were not significantly different at time of switch. No adverse events related to the monitoring strategy were reported.<h4>Conclusions</h4>The 3-year rates of clinical failure and loss of treatment options did not differ between strategies although the longer-term consequences of CD4 monitoring would need to be investigated. These results provide reassurance to treatment programs currently based on CD4 monitoring as VL measurement becomes more affordable and feasible in resource-limited settings.<h4>Trial registration</h4>ClinicalTrials.govNCT00162682 Please see later in the article for the Editors' Summary. |
| format |
article |
| author |
Gonzague Jourdain Sophie Le Cœur Nicole Ngo-Giang-Huong Patrinee Traisathit Tim R Cressey Federica Fregonese Baptiste Leurent Intira J Collins Intira J Collins Malee Techapornroong Sukit Banchongkit Sudanee Buranabanjasatean Guttiga Halue Ampaipith Nilmanat Nuananong Luekamlung Virat Klinbuayaem Apichat Chutanunta Pacharee Kantipong Chureeratana Bowonwatanuwong Rittha Lertkoonalak Prattana Leenasirimakul Somboon Tansuphasawasdikul Pensiriwan Sang-A-Gad Panita Pathipvanich Srisuda Thongbuaban Pakorn Wittayapraparat Naree Eiamsirikit Yuwadee Buranawanitchakorn Naruepon Yutthakasemsunt Narong Winiyakul Luc Decker Sylvaine Barbier Suporn Koetsawang Wasna Sirirungsi Kenneth McIntosh Sombat Thanprasertsuk Marc Lallemant PHPT-3 study team |
| author_facet |
Gonzague Jourdain Sophie Le Cœur Nicole Ngo-Giang-Huong Patrinee Traisathit Tim R Cressey Federica Fregonese Baptiste Leurent Intira J Collins Intira J Collins Malee Techapornroong Sukit Banchongkit Sudanee Buranabanjasatean Guttiga Halue Ampaipith Nilmanat Nuananong Luekamlung Virat Klinbuayaem Apichat Chutanunta Pacharee Kantipong Chureeratana Bowonwatanuwong Rittha Lertkoonalak Prattana Leenasirimakul Somboon Tansuphasawasdikul Pensiriwan Sang-A-Gad Panita Pathipvanich Srisuda Thongbuaban Pakorn Wittayapraparat Naree Eiamsirikit Yuwadee Buranawanitchakorn Naruepon Yutthakasemsunt Narong Winiyakul Luc Decker Sylvaine Barbier Suporn Koetsawang Wasna Sirirungsi Kenneth McIntosh Sombat Thanprasertsuk Marc Lallemant PHPT-3 study team |
| author_sort |
Gonzague Jourdain |
| title |
Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. |
| title_short |
Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. |
| title_full |
Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. |
| title_fullStr |
Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. |
| title_full_unstemmed |
Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. |
| title_sort |
switching hiv treatment in adults based on cd4 count versus viral load monitoring: a randomized, non-inferiority trial in thailand. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/34088c5dc0be4ad7831a7675568d645b |
| work_keys_str_mv |
AT gonzaguejourdain switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT sophielecœur switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT nicolengogianghuong switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT patrineetraisathit switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT timrcressey switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT federicafregonese switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT baptisteleurent switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT intirajcollins switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT intirajcollins switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT maleetechapornroong switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT sukitbanchongkit switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT sudaneeburanabanjasatean switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT guttigahalue switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT ampaipithnilmanat switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT nuananongluekamlung switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT viratklinbuayaem switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT apichatchutanunta switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT pachareekantipong switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT chureeratanabowonwatanuwong switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT ritthalertkoonalak switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT prattanaleenasirimakul switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT somboontansuphasawasdikul switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT pensiriwansangagad switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT panitapathipvanich switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT srisudathongbuaban switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT pakornwittayapraparat switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT nareeeiamsirikit switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT yuwadeeburanawanitchakorn switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT narueponyutthakasemsunt switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT narongwiniyakul switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT lucdecker switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT sylvainebarbier switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT supornkoetsawang switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT wasnasirirungsi switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT kennethmcintosh switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT sombatthanprasertsuk switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT marclallemant switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand AT phpt3studyteam switchinghivtreatmentinadultsbasedoncd4countversusviralloadmonitoringarandomizednoninferioritytrialinthailand |
| _version_ |
1718424778519347200 |
| spelling |
oai:doaj.org-article:34088c5dc0be4ad7831a7675568d645b2021-11-18T05:43:11ZSwitching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand.1549-12771549-167610.1371/journal.pmed.1001494https://doaj.org/article/34088c5dc0be4ad7831a7675568d645b2013-08-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23940461/?tool=EBIhttps://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4>Viral load (VL) is recommended for monitoring the response to highly active antiretroviral therapy (HAART) but is not routinely available in most low- and middle-income countries. The purpose of the study was to determine whether a CD4-based monitoring and switching strategy would provide a similar clinical outcome compared to the standard VL-based strategy in Thailand.<h4>Methods and findings</h4>The Programs for HIV Prevention and Treatment (PHPT-3) non-inferiority randomized clinical trial compared a treatment switching strategy based on CD4-only (CD4) monitoring versus viral-load (VL). Consenting participants were antiretroviral-naïve HIV-infected adults (CD4 count 50-250/mm(3)) initiating non-nucleotide reverse transcriptase inhibitor (NNRTI)-based therapy. Randomization, stratified by site (21 public hospitals), was performed centrally after enrollment. Clinicians were unaware of the VL values of patients randomized to the CD4 arm. Participants switched to second-line combination with confirmed CD4 decline >30% from peak (within 200 cells from baseline) in the CD4 arm, or confirmed VL >400 copies/ml in the VL arm. Primary endpoint was clinical failure at 3 years, defined as death, new AIDS-defining event, or CD4 <50 cells/mm(3). The 3-year Kaplan-Meier cumulative risks of clinical failure were compared for non-inferiority with a margin of 7.4%. In the intent to treat analysis, data were censored at the date of death or at last visit. The secondary endpoints were difference in future-drug-option (FDO) score, a measure of resistance profiles, virologic and immunologic responses, and the safety and tolerance of HAART. 716 participants were randomized, 356 to VL monitoring and 360 to CD4 monitoring. At 3 years, 319 participants (90%) in VL and 326 (91%) in CD4 were alive and on follow-up. The cumulative risk of clinical failure was 8.0% (95% CI 5.6-11.4) in VL versus 7.4% (5.1-10.7) in CD4, and the upper-limit of the one-sided 95% CI of the difference was 3.4%, meeting the pre-determined non-inferiority criterion. Probability of switch for study criteria was 5.2% (3.2-8.4) in VL versus 7.5% (5.0-11.1) in CD4 (p=0.097). Median time from treatment initiation to switch was 11.7 months (7.7-19.4) in VL and 24.7 months (15.9-35.0) in CD4 (p=0.001). The median duration of viremia >400 copies/ml at switch was 7.2 months (5.8-8.0) in VL versus 15.8 months (8.5-20.4) in CD4 (p=0.002). FDO scores were not significantly different at time of switch. No adverse events related to the monitoring strategy were reported.<h4>Conclusions</h4>The 3-year rates of clinical failure and loss of treatment options did not differ between strategies although the longer-term consequences of CD4 monitoring would need to be investigated. These results provide reassurance to treatment programs currently based on CD4 monitoring as VL measurement becomes more affordable and feasible in resource-limited settings.<h4>Trial registration</h4>ClinicalTrials.govNCT00162682 Please see later in the article for the Editors' Summary.Gonzague JourdainSophie Le CœurNicole Ngo-Giang-HuongPatrinee TraisathitTim R CresseyFederica FregoneseBaptiste LeurentIntira J CollinsIntira J CollinsMalee TechapornroongSukit BanchongkitSudanee BuranabanjasateanGuttiga HalueAmpaipith NilmanatNuananong LuekamlungVirat KlinbuayaemApichat ChutanuntaPacharee KantipongChureeratana BowonwatanuwongRittha LertkoonalakPrattana LeenasirimakulSomboon TansuphasawasdikulPensiriwan Sang-A-GadPanita PathipvanichSrisuda ThongbuabanPakorn WittayapraparatNaree EiamsirikitYuwadee BuranawanitchakornNaruepon YutthakasemsuntNarong WiniyakulLuc DeckerSylvaine BarbierSuporn KoetsawangWasna SirirungsiKenneth McIntoshSombat ThanprasertsukMarc LallemantPHPT-3 study teamPublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 10, Iss 8, p e1001494 (2013) |